Comparison of the anti-inflammatory effects of Cilomilast, Budesonide and a p38 Mitogen activated protein kinase inhibitor in COPD lung tissue macrophages

BMC Pharmacology and Toxicology

Volumn 13, Issue , 2012, Pages

  Ratcliffe, Marianne Jennifer ^a   Dougall, Iain Gordon ^b  

^a ASTRAZENECA   (United Kingdom)

^b IGD Consultancy Limited   (United Kingdom)

Author keywords

BIRB 796; Budesonide; COPD; Lung; Macrophage; P38 MAPK; PDEIV; Steroid insensitivity; TNF

Indexed keywords

BUDESONIDE; CILOMILAST; DORAMAPIMOD; INTERLEUKIN 6; TUMOR NECROSIS FACTOR ALPHA; ANTIINFLAMMATORY AGENT; CYCLOHEXANECARBOXYLIC ACID DERIVATIVE; LIPOPOLYSACCHARIDE; MITOGEN ACTIVATED PROTEIN KINASE P38; NAPHTHALENE DERIVATIVE; NITRILE; PHOSPHODIESTERASE IV INHIBITOR; PROTEIN KINASE INHIBITOR; PYRAZOLE DERIVATIVE;

ADULT; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ARTICLE; CYTOKINE RELEASE; DRUG EFFICACY; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; LUNG PARENCHYMA; LUNG TRANSPLANTATION; MACROPHAGE; MALE; TREATMENT RESPONSE; CELL CULTURE; COMPARATIVE STUDY; DRUG ANTAGONISM; DRUG EFFECT; IMMUNOLOGY; LUNG ALVEOLUS MACROPHAGE; MIDDLE AGED;

ANTI-INFLAMMATORY AGENTS; BUDESONIDE; CELLS, CULTURED; CYCLOHEXANECARBOXYLIC ACIDS; FEMALE; HUMANS; INTERLEUKIN-6; LIPOPOLYSACCHARIDES; MACROPHAGES, ALVEOLAR; MALE; MIDDLE AGED; NAPHTHALENES; NITRILES; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHODIESTERASE 4 INHIBITORS; PROTEIN KINASE INHIBITORS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; PYRAZOLES; TUMOR NECROSIS FACTOR-ALPHA;

MLCS; MLOWN;

EID: 84876325780     PISSN: 20506511     EISSN: None     Source Type: Journal    
DOI: 10.1186/2050-6511-13-15     Document Type: Article

References (27)

1. Buist AS, McBurnie MA, Vollmer WM, Gillespie S, Burney P, Mannino DM, Menezes AM, Sullivan SD, Lee TA, Weiss KB, Jensen RL, Marks GB, Gulsvik A, Nizankowska-Mogilnicka E. International variation in the prevalence of COPD (The BOLD Study): a population-based prevalence study. Lancet 2007, 370:741-750. 10.1016/S0140-6736(07)61377-4, 17765523.
2. Calverley PMA, Anderson JA, Celli B, Ferguson GT, Jenkins C, Jones PW, Yates JC, Vestbo J. Salmeterol and Fluticasone Propionate and Survival in Chronic Obstructive Pulmonary Disease. N Engl J Med 2007, 356:775-789. 10.1056/NEJMoa063070, 17314337.
3. Gan WQ, Man SP, Sin D. Effects of inhaled corticosteroids on sputum cell counts in stable chronic obstructive pulmonary disease: a systematic review and a meta-analysis. BMC Pulm Med 2005, 5:3. 10.1186/1471-2466-5-3, 552309, 15707484.
4. Jen R, Rennard SI. Effects of inhaled corticosteroids on airway inflammation in chronic obstructive pulmonary disease: a systematic review and meta-analysis. International Journal of Chronic Pulmonary Obstructive Disease 2012, 7:587-595.
5. Barnes PJ. New Concepts in Chronic Obstructive Pulmonary Disease. Annu Rev Med 2003, 54:113-129. 10.1146/annurev.med.54.101601.152209, 12359824.
6. Culpitt SV, Rogers DF, Shah P, De Matos C, Russell REK, Donnelly LE, Barnes PJ. Impaired Inhibition by Dexamethasone of Cytokine Release by Alveolar Macrophages from Patients with Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med 2003, 167:24-31. 10.1164/rccm.200204-298OC, 12406856.
7. Adcock IM, Barnes PJ. Molecular mechanisms of corticosteroid resistance. Chest 2008, 134:394-401. 10.1378/chest.08-0440, 18682458.
8. Gamble E, Grootendorst DC, Brightling CE, Troy S, Qiu Y, Zhu J, Parker D, Matin D, Majumdar S, Vignola AM, Kroegel C, Morell F, Hansel TT, Rennard SI, Compton C, Amit O, Tat T, Edelson J, Pavord ID, Rabe KF, Barnes NC, Jeffery PK. Antiinflammatory Effects of the Phosphodiesterase-4 Inhibitor Cilomilast (Ariflo) in Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med 2003, 168:976-982. 10.1164/rccm.200212-1490OC, 12816740.
9. Fabbri LM, Calverley PM, Izquierdo-Alonso JL, Bundschuh DS, Brose M, Martinez FJ, Rabe KF. Roflumilast in moderate-to-severe chronic obstructive pulmonary disease treated with longacting bronchodilators: two randomised clinical trials. Lancet 2009, 374:695-703. 10.1016/S0140-6736(09)61252-6, 19716961.
10. Calverley PM, Rabe KF, Goehring U, Kristiansen S, Fabbri LM, Martinez FJ. Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials. Lancet 2009, 374:685-694. 10.1016/S0140-6736(09)61255-1, 19716960.
11. Kumar S, Boehm J, Lee JC. p38 MAP kinases: key signalling molecules as therapeutic targets for inflammatory diseases. Nat Rev Drug Discov 2003, 2:717-726. 10.1038/nrd1177, 12951578.
12. Singh D, Smyth L, Borrill Z, Sweeney L, Tal-Singer R. A Randomized, Placebo-Controlled Study of the Effects of the p38 MAPK Inhibitor SB-681323 on Blood Biomarkers of Inflammation in COPD Patients. J Clin Pharmacol 2010, 50:94-100. 10.1177/0091270009347873, 19880675.
13. Lomas DA, Lipson DA, Miller BE, Willits L, Keene O, Barnacle H, Barnes NC, Tal-Singer R. on behalf of the Losmapimod Study Investigators: An Oral Inhibitor of p38 MAP Kinase Reduces Plasma Fibrinogen in Patients With Chronic Obstructive Pulmonary Disease. J Clin Pharmacol 2012, 52:416-424. 10.1177/0091270010397050, 22090363.
14. Smith SJ, Fenwick PS, Nicholson AG, Kirschenbaum F, Finney-Hayward TK, Higgins LS, Giembycz MA, Barnes PJ, Donnelly LE. Inhibitory effect of p38 mitogen-activated protein kinase inhibitors on cytokine release from human macrophages. Br J Pharmacol 2006, 149:393-404. 10.1038/sj.bjp.0706885, 1978438, 16953188.
15. Kent LM, Smyth LJ, Plumb J, Clayton CL, Fox SM, Ray DW, Farrow SN, Singh D. Inhibition of lipopolysaccharide-stimulated chronic obstructive pulmonary disease macrophage inflammatory gene expression by dexamethasone and the p38 mitogen-activated protein kinase inhibitor N-cyano-N'-(2-{[8-(2,6-difluorophenyl)-4-(4-fluoro-2-methylphenyl)-7-oxo-7,8-dihydropyrido[2,3-d] pyrimidin-2-yl]amino}ethyl)guanidine (SB706504). J Pharmacol Exp Ther 2009, 328:458-468. 10.1124/jpet.108.142950, 2682286, 19004925.
16. Patel IS, Seemungal TAR, Wilks M, Lloyd-Owen SJ, Donaldson GC, Wedzicha JA. Relationship between bacterial colonisation and the frequency, character, and severity of COPD exacerbations. Thorax 2002, 57:759-764. 10.1136/thorax.57.9.759, 1746426, 12200518.
17. Keatings V, Collins P, Scott D, Barnes P. Differences in interleukin-8 and tumor necrosis factor-alpha in induced sputum from patients with chronic obstructive pulmonary disease or asthma. Am J Respir Crit Care Med 1996, 153:530-534.
18. Wedzicha JA, Seemungal TAR, MacCallum PK, Paul EA, Donaldson GC, Bhowmik A, Jeffries DJ, Meade TW. Acute Exacerbations of Chronic Obstructive Pulmonary Disease Are Accompanied by Elevations of Plasma Fibrinogen and Serum IL-6 Levels. Thromb Haemost 2000, 84:210-215.
19. Gingo MR, Silveira LJ, Miller YE, Friedlander AL, Cosgrove GP, Chan ED, Maier LA, Bowler RP. Tumour necrosis factor gene polymorphisms are associated with COPD. Eur Respir J 2008, 31:1005-1012. 10.1183/09031936.00100307, 18256059.
20. He J, Foreman MG, Shumansky K, Zhang X, Akhabir L, Sin DD, Man SFP, DeMeo DL, Litonjua AA, Silverman EK, Connett JE, Anthonisen NR, Wise RA, Paré PD, Sandford AJ. Associations of IL6 polymorphisms with lung function decline and COPD. Thorax 2009, 64:698-704. 10.1136/thx.2008.111278, 2859187, 19359268.
21. Gantner F, Kupferschmidt R, Schudt C, Wendel A, Hatzelmann A. In vitro differentiation of human monocytes to macrophages: change of PDE profile and its relationship to suppression of tumour necrosis factor-α release by PDE inhibitors. Br J Pharmacol 1997, 121:221-231. 10.1038/sj.bjp.0701124, 1564680, 9154331.
22. Hatzelmann A, Schudt C. Anti-Inflammatory and Immunomodulatory Potential of the Novel PDE4 Inhibitor Roflumilast in Vitro. J Pharmacol Exp Ther 2001, 297:267-279.
23. Armstrong J, Sargent C, Singh D. Glucocorticoid sensitivity of lipopolysaccharide-stimulated chronic obstructive pulmonary disease alveolar macrophages. Clin Exp Immunol 2009, 158:74-83. 10.1111/j.1365-2249.2009.03986.x, 2759061, 19737233.
24. Renda T, Baraldo S, Pelaia G, Bazzan E, Turato G, Papi A, Maestrelli P, Maselli R, Vatrella A, Fabbri LM, Zuin R, Marsico SA, Saetta M. Increased activation of p38 MAPK in COPD. Eur Respir J 2008, 31:62-69. 10.1183/09031936.00036707, 17959643.
25. Millan DS, Bunnage ME, Burrows JL, Butcher KJ, Dodd PG, Evans TJ, Fairman DA, Hughes SJ, Kilty IC, Lemaitre A, Lewthwaite RA, Mahnke A, Mathias JP, Philip J, Smith RT, Stefaniak MH, Yeadon M, Phillips C. Design and Synthesis of Inhaled p38 Inhibitors for the Treatment of Chronic Obstructive Pulmonary Disease. J Med Chem 2011, 54:7797-7814. 10.1021/jm200677b, 21888439.
26. Bhavsar P, Khorasani N, Hew M, Johnson M, Chung KF. Effect of p38 MAPK inhibition on corticosteroid suppression of cytokine release in severe asthma. Eur Respir J 2010, 35:750-756. 10.1183/09031936.00071309, 19840967.
27. Armstrong J, Harbron C, Lea S, Booth G, Cadden P, Wreggett KA, Singh D. Syngergistic effects of p38 mitogen activated protein kinase inhibition with a corticosteroid in Alveolar Macrophages from patients with Chronic Obstructive Pulmonary Disease. J Pharmacol Exp Ther 2011, 338:732. 10.1124/jpet.111.180737, 21610141.